Novo Nordisk and Hims & Hers struck a deal to list Novo’s GLP‑1 medicines on Hims’ telehealth platform at the same prices available through other telehealth providers. Under the agreement Hims will stop promoting compounded GLP‑1 alternatives and offer existing patients the option to switch to FDA‑approved products; Novo will dismiss its patent suit while reserving the right to refile. Novo CEO Mike Doustdar framed the pact as an access expansion for patients, while regulators have been tightening oversight around compounding and telehealth distribution. The deal ends a public feud that had escalated into litigation and regulatory attention, and it reallocates a direct commercial channel for Novo amid competitive pressure from Lilly and compounding firms. Quick technical note: GLP‑1 receptor agonists are injectable or oral therapies that regulate blood glucose and suppress appetite; they are central to current obesity and diabetes drug markets.